Eradication of Spider Veins and Varicose Veins: Sclerotherapy & Laser Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Spider veins (telangiectasias) and varicose veins are abnormally dilated, visible blood vessels beneath the skin surface that affect an estimated 20–30% of adults — with prevalence rising to 50–55% in women over 50. While spider veins are fine, web-like red, purple, or blue vessels visible on the legs and face, varicose veins are larger, bulging, rope-like structures that protrude above the skin surface and frequently cause symptoms including aching, heaviness, swelling, itching, and leg cramps.

Both conditions result from chronic venous insufficiency — failure of the one-way valves within leg veins that normally prevent blood from flowing backward (reflux) under gravitational pressure. When valves fail, blood pools in the vein wall, generating abnormal distending pressure that progressively dilates and elongates the vessel until it becomes visibly tortuous.

The eradication of unsightly blood vessels encompasses several evidence-based procedures that destroy or seal affected vessels so they are gradually absorbed by the body over weeks to months. These include:

• Sclerotherapy: Injection of a chemical irritant (sclerosant) directly into the vein to damage its endothelial lining and induce fibrotic closure
• Laser vein therapy: Intense focused light energy heats and coagulates the vessel wall without a needle
• Radiofrequency ablation (RFA) and endovenous laser ablation (EVLA): Catheter-based thermal techniques for larger truncal varicose veins
• Foam sclerotherapy: Sclerosant mixed with air or carbon dioxide to create foam with greater contact efficiency for larger veins

These treatments are performed by dermatologists, plastic surgeons, and vascular specialists in outpatient clinic settings. They improve cosmetic appearance, relieve symptoms of venous insufficiency, and prevent complications of untreated varicose veins including venous leg ulcers, bleeding, and superficial thrombophlebitis.

The eradication spectrum covers the full range of superficial venous insufficiency from fine facial telangiectasias to bulky symptomatic varicose veins.

• Spider Veins (Telangiectasias): Dilated superficial capillaries forming reddish or purplish web-like networks, typically 0.1–1 mm in diameter. Most commonly appear on the thighs, calves, and ankles, but also on the face (particularly the nose, cheeks, and chin). Primarily cosmetic but may cause localised burning or itching. Highly amenable to sclerotherapy and laser therapy.
• Reticular Veins: Slightly larger, flat blue-green veins (1–3 mm diameter) that often feed clusters of spider veins. Typically treated with liquid sclerotherapy or fine-needle foam sclerotherapy to collapse the feeder vessel and prevent spider vein recurrence.
• Varicose Veins: Dilated, tortuous superficial veins exceeding 3 mm diameter, most commonly the great saphenous vein (GSV) or its tributaries. Cause aching, heaviness, oedema, and skin changes. Trunk varicose veins are treated with endovenous thermal ablation (radiofrequency or laser); smaller branch varicosities with foam sclerotherapy or ambulatory phlebectomy.
• Facial Telangiectasias: Fine red or purple capillaries on the nose, cheeks, and chin commonly associated with rosacea, sun damage, or genetic predisposition. Treated with intense pulsed light (IPL), Nd:YAG laser, or pulsed-dye laser rather than sclerotherapy (injection into facial vessels carries risk of skin necrosis).
• Venous Malformations: Congenital collections of abnormal venous channels; treated with direct percutaneous sclerotherapy (using ethanol, sotradecol, or bleomycin) by an interventional radiologist.
• Post-Sclerotherapy Matting: Fine new telangiectasias that occasionally appear at the injection site weeks after sclerotherapy; treated with additional laser sessions or very-low-concentration sclerosant.

Most adults with spider veins or varicose veins are suitable for one or more vein eradication techniques. A detailed history and physical examination — and often a venous duplex ultrasound — guides treatment selection.

Suitable candidates include:

• Adults with spider veins, reticular veins, or varicose veins causing cosmetic concern and/or symptoms (aching, heaviness, itching, swelling)
• Patients in whom underlying great saphenous vein (GSV) or small saphenous vein (SSV) incompetence has been excluded (or treated first) by duplex ultrasound
• Patients with C2–C4 chronic venous disease on the CEAP classification (varicose veins to skin changes, before active ulceration)
• Patients with venous leg oedema or skin changes (lipodermatosclerosis) at risk of ulceration who may benefit from vein treatment as part of wound prevention strategy

Relative contraindications:

• Pregnancy and breastfeeding: Sclerotherapy is deferred until 3 months after delivery; many vein cases improve spontaneously post-partum
• Deep vein thrombosis (DVT) history: Require specialist haematology review and thrombophilia testing before foam sclerotherapy (small risk of paradoxical embolism via patent foramen ovale)
• Known allergy to sclerosant agent: Alternative sclerosant or laser therapy substituted
• Severely immobile patients: Compression therapy after sclerotherapy is less effective; treatment is modified accordingly
• Poorly controlled peripheral arterial disease: Compression stockings may compromise arterial perfusion; ABPI (ankle-brachial pressure index) measurement required before prescribing compression

Duplex ultrasound: Essential for all varicose veins before treatment to map the venous anatomy, identify sites of incompetent valves, and detect any co-existing DVT. Not required for isolated small spider veins with no palpable varicosities.

Treatment is tailored to the vessel type, size, location, and whether the underlying truncal vein is competent. Most patients require a combination of techniques for optimal results.

• Liquid Sclerotherapy (Microsclerotherapy): The gold-standard treatment for spider veins and reticular veins on the legs. A sclerosant solution — most commonly polidocanol (0.25–1%) or sodium tetradecyl sulphate (STS, 0.1–0.5%) — is injected through a very fine needle (30 gauge) directly into multiple vessel clusters. The sclerosant chemically irritates the endothelial lining, causing spasm and then fibrosis of the vessel. Treated vessels turn white immediately (vasospasm), then fade over 3–6 weeks. Multiple injection sites per session; 15–30 minutes per session. Most patients require 2–4 sessions for complete clearance of a treated area.
• Foam Sclerotherapy: Sclerosant is mixed with air or CO2 using the Tessari technique (two syringes, one stopcock) to create a foam that displaces blood from the vein lumen, maximising sclerosant contact with the vessel wall. Foam sclerotherapy is more effective than liquid for reticular veins and small varicose veins (2–6 mm) and is used under ultrasound guidance (echo-guided foam sclerotherapy) for vessels not visible from the surface. A single foam treatment can eliminate significantly larger vessel volumes than liquid.
• Laser Vein Therapy (External Laser): Intense pulsed light (IPL), pulsed-dye laser (PDL, 585/595 nm), or Nd:YAG laser (1064 nm) targets oxyhaemoglobin in red vessels (for fine telangiectasias) or penetrates more deeply for blue-purple larger vessels. The light energy is absorbed selectively, heating and coagulating the vessel wall without damaging surrounding skin. Ideal for facial telangiectasias and very fine leg spider veins where injection with a needle is impractical. Three to six sessions typically required. Transient purpura (bruising) is expected after pulsed-dye laser.
• Radiofrequency Ablation (RFA) / Endovenous Laser Ablation (EVLA): For great saphenous vein or small saphenous vein incompetence driving multiple varicose veins. A catheter is advanced into the truncal vein under ultrasound guidance; thermal energy (RF or laser) is delivered along the vein length under local tumescent anaesthesia, sealing the vein from inside. Once the truncal reflux is eliminated, residual varicosities and spider veins are then treated with sclerotherapy or ambulatory phlebectomy in subsequent sessions.

Treatment of spider veins and varicose veins delivers benefits that extend beyond cosmetic improvement to meaningful symptom relief and prevention of disease progression.

• Cosmetic Improvement: Spider vein sclerotherapy achieves 60–80% clearance per treated area per session, with cumulative clearance of 80–95% after a full treatment course. Facial laser therapy reduces visible telangiectasias by 70–90%. Improved appearance of the legs reduces social and psychological impact of vein disease, which disproportionately affects women and is associated with avoidance of activities and reduced quality of life.
• Symptom Relief: Varicose vein treatment reliably reduces aching (85–90% improvement), heaviness, leg swelling (oedema), night cramps, and itching — symptoms that significantly impair daily functioning and sleep quality. The Aberdeen Varicose Vein Questionnaire demonstrates clinically significant quality-of-life improvement after endovenous ablation.
• Prevention of Disease Progression: Untreated varicose veins and chronic venous insufficiency progress over years to skin changes (lipodermatosclerosis, haemosiderosis, atrophie blanche) and ultimately to venous leg ulcers — the most common chronic wound in adults over 70. Early treatment arrests this progression and reduces the lifetime cost and burden of care.
• Minimal Downtime: Sclerotherapy and external laser therapy are walk-in, walk-out procedures. Patients return to work and most activities the same day. Endovenous ablation requires 1–2 days of light activity but no hospitalisation.
• No Scarring: Modern sclerotherapy and laser techniques do not leave visible scars. Mild post-injection bruising and temporary hyperpigmentation resolve within 4–12 weeks in most patients.
• Durable Results: Properly treated veins do not recur. New veins can develop over time due to ongoing venous hypertension or genetic predisposition, but treated vessels are permanently eliminated.

Sclerotherapy and laser vein treatments are low-risk outpatient procedures, but patients should understand the expected temporary side effects and uncommon complications.

Common expected side effects (temporary):

• Bruising (Haematoma): Minor bruising at injection sites is universal and resolves within 1–4 weeks. Ice application and compression minimise bruising.
• Hyperpigmentation: Brown staining along treated vessels from haemosiderin (breakdown product of red blood cells) deposited in the skin. Occurs in 10–30% of patients and may take 3–12 months to fully resolve. Very rarely permanent. Risk is reduced by early aspiration of trapped blood (coagulum) from treated vessels at 3–4 weeks.
• Localised Pain / Burning: Mild burning sensation at injection sites during and immediately after sclerosant injection, lasting seconds to minutes. Compression and elevation after treatment minimise discomfort.
• Matting: Fine new telangiectasias appearing in the treated area 4–8 weeks after sclerotherapy in approximately 15–20% of patients. Usually resolves spontaneously within 6 months or responds to additional laser treatment. Attributed to angiogenesis triggered by local inflammation.

Uncommon but significant complications:

• Cutaneous Necrosis: Skin breakdown caused by inadvertent injection of sclerosant into a very superficial vessel or arterial branch. Occurs in less than 0.1% of injections. Results in a small ulcer that heals with a scar over 6–12 weeks.
• Thrombophlebitis: Inflammatory clotting in treated vessels extending beyond the treated segment; presents as a tender, cord-like swelling. Treated with anti-inflammatory medication and compression.
• Systemic Allergic Reaction: Rare anaphylaxis to sclerosant; all treatment clinics maintain resuscitation equipment. Incidence approximately 1 in 10,000 sessions.
• Deep Vein Thrombosis (DVT): Very rare complication of foam sclerotherapy involving large veins. Patients are advised to walk immediately after treatment and wear compression stockings to reduce risk.

Post-treatment care significantly influences the final cosmetic outcome and comfort during the healing period. Adherence to compression, activity, and skin care instructions optimises results.

Immediately after sclerotherapy:

• Compression bandages or graduated compression stockings (class 2, 23–32 mmHg) are applied immediately after injection and worn continuously for 48–72 hours, then during waking hours for 2–4 weeks. Compression maintains the collapsed vessel walls in contact and reduces bruising and hyperpigmentation.
• Walking for 20–30 minutes immediately after the session activates the calf muscle pump, aids sclerosant dispersal, and reduces DVT risk.
• Avoid high-impact exercise, saunas, hot baths, sunbathing, and prolonged standing or sitting for 48–72 hours after treatment.
• High SPF sunscreen (SPF 50+) applied to treated areas whenever outdoors for 8–12 weeks to prevent UV-triggered hyperpigmentation at injection sites.

Follow-up visits:

• Review at 4–6 weeks: assessment of initial clearance, trapped coagulum aspiration if needed, and further treatment to residual vessels or newly identified feeder veins.
• Repeat sessions at 4–6 week intervals until the treatment goal is achieved. Most leg spider vein cases require 2–4 sessions; more extensive varicose vein disease requires 4–6 sessions.
• Final review 3–6 months after the last session when all hyperpigmentation has settled and the true final result can be assessed.

Long-term maintenance: New spider veins may develop over subsequent years due to ongoing venous hypertension or genetic tendency. Annual review appointments allow early treatment of new vessels before they enlarge. Wearing medical compression stockings daily significantly slows the rate of new vein formation.

The cost of vein eradication treatment varies by technique, the number of sessions required, the extent of disease, and the country and type of practice (medical vs. cosmetic/aesthetic clinic).

• United States: Sclerotherapy per session: $150–$500 (small spider vein areas) to $800–$1,500 (extensive coverage). Laser vein therapy per session: $300–$600. Endovenous radiofrequency or laser ablation per leg: $3,000–$5,000. Insurance coverage: cosmetic sclerotherapy for spider veins is typically not covered; symptomatic varicose vein treatment (C2S classification with duplex-confirmed reflux) is usually covered under medical insurance with prior authorisation.
• United Kingdom: NHS treats symptomatic varicose veins with endovenous ablation or foam sclerotherapy when NICE criteria are met (significant impact on quality of life, skin changes, or complications). Private clinic prices: £200–£500 per sclerotherapy session; £1,500–£3,000 for endovenous ablation per leg.
• India: Sclerotherapy per session: ₹3,000–₹12,000 ($35–$145). Foam sclerotherapy: ₹5,000–₹20,000 ($60–$240). Laser vein therapy per session: ₹6,000–₹20,000 ($70–$240). Radiofrequency ablation per leg: ₹40,000–₹80,000 ($480–$960). Complete multi-session varicose vein packages at leading dermatology and vascular surgery centres in Mumbai, Delhi, and Bangalore offer comprehensive treatment for $500–$1,500 total — compared to $8,000–$20,000 in the US for equivalent treatment.
• Thailand: Sclerotherapy per session: $150–$400 at Bangkok's internationally accredited medical aesthetics and vascular clinics. Complete treatment packages from $600–$2,000.
• Dubai / UAE: $200–$600 per sclerotherapy session at licensed dermatology clinics; endovenous ablation $2,500–$5,000 per leg.

What affects total cost: Number of sessions (determined by severity), size of treatment area, use of duplex ultrasound guidance for foam injections (adds $100–$200 per session), facility type (hospital vs. standalone clinic), and whether concurrent endovenous ablation of a truncal vein is required before spider vein treatment is commenced.

Several non-procedural and procedural alternatives complement or replace sclerotherapy and laser therapy depending on vessel type, patient preference, and clinical context.

• Compression Therapy (Medical Compression Stockings): Class 2 graduated compression stockings (23–32 mmHg) do not eradicate existing varicose veins or spider veins but significantly reduce symptoms (aching, swelling, heaviness) by counteracting venous hypertension. Also used to slow progression of new vessel formation and to maintain results after treatment. Non-invasive, inexpensive, but requires daily adherence which many patients find difficult.
• Ambulatory Phlebectomy (Microphlebectomy): Bulging varicose vein branches that are too large for foam sclerotherapy are removed through multiple micro-incisions (2–3 mm) under local tumescent anaesthesia in an outpatient procedure. The vein is removed in segments using a small hook. Excellent cosmetic outcomes; no sutures required. Often performed simultaneously with radiofrequency ablation of the truncal vein.
• Intense Pulsed Light (IPL) Therapy: Broadband light in the 500–1200 nm spectrum targets haemoglobin in fine facial and leg telangiectasias. Less selective than dedicated laser but versatile; simultaneously treats background redness, sun damage, and pigmentation. Typically 3–5 sessions required. Preferred for diffuse facial redness in rosacea patients where individual vessel targeting is impractical.
• VeinGogh Ohmic Thermolysis: A very fine probe delivering low-level radiofrequency current directly to superficial spider veins 0.1–0.4 mm in diameter that are too small for needle injection. Useful for very fine "resistance veins" that do not respond to conventional sclerotherapy.
• Lifestyle Modifications: Regular walking, weight management, leg elevation, and avoidance of prolonged standing or sitting address the underlying venous hypertension driving new vessel formation. These measures do not eradicate existing veins but complement procedural treatment by reducing recurrence rates.
• Pharmacotherapy (Venotonics): Oral medications such as micronised purified flavonoid fraction (Daflon), horse chestnut seed extract (escin), and rutosides reduce capillary permeability and venous tone, providing modest symptomatic relief without eradicating visible vessels. Used as adjuncts to compression and procedural treatment rather than standalone therapy.